Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19013480 | 0.83 | USP2 (0.42) | ESR2NR1H2MAPK1USP2SMN1; SMN2 | |
| SCHEMBL18556946 | 0.82 | ESR2 (0.50) | ESR2NR1H2MAPK1USP2SMN1; SMN2 | |
| SCHEMBL12519920 | 0.82 | ESR2 (0.47) | ESR2NR1H2MAPK1USP2SMN1; SMN2 | |
| SCHEMBL25342701 | 0.81 | ESR2 (0.49) | ESR2NR1H2MAPK1USP2SMN1; SMN2 | |
| SCHEMBL30262739 | 0.81 | ESR2 (0.46) | ESR2NR1H2MAPK1USP2SMN1; SMN2 | |
| SCHEMBL28060814 | 0.81 | ESR2 (0.46) | ESR2NR1H2MAPK1USP2SMN1; SMN2 | |
| SCHEMBL6216656 | 0.79 | NR1H2 (0.47) | ESR2NR1H2MAPK1USP2SMN1; SMN2 | |
| SCHEMBL2270068 | 0.79 | ESR2 (0.45) | ESR2NR1H2MAPK1USP2SMN1; SMN2 | |
| SCHEMBL6667095 | 0.79 | ESR2 (0.45) | ESR2NR1H2MAPK1USP2SMN1; SMN2 | |
| SCHEMBL29333593 | 0.79 | ESR2 (0.48) | ESR2NR1H2MAPK1USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2688890-B1 | SUBSTITUTED FUSED TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LTD (IN) | 2017-08-30 | — | — | EP | disclosed |
| WO-2017106352-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | RAZE THERAPEUTICS, INC. (US) | 2017-06-22 | — | — | WO | disclosed |
| US-9593115-B2 | Substituted fused tricyclic compounds, compositions, and medicinal applications thereof | ADVINUS THERAPEUTICS LTD. | 2017-03-14 | — | — | US | disclosed |
| US-9593115-B2 | Substituted fused tricyclic compounds, compositions, and medicinal applications thereof | ADVINUS THERAPEUTICS LTD. | 2017-03-14 | — | — | US | disclosed |
| US-20150239886-A1 | SUBSTITUTED FUSED TRICYCLIC COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD. (IN) | 2015-08-27 | — | — | US | disclosed |
| US-20150239886-A1 | SUBSTITUTED FUSED TRICYCLIC COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD. (IN) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239886-A1 | SUBSTITUTED FUSED TRICYCLIC COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF | JAK1, MALT1, JAK2 | ESR2 1164/4885NR1H2 1404/4885MAPK1 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.